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Background: Motor neurone disease (MND) is a devastating illness which leads to muscle weakness and death,
usually within 2-3 years of symptom onset. Respiratory insufficiency is a common cause of morbidity, particularly in
later stages of MND and respiratory complications are the leading cause of mortality in MND patients. Non Invasive
Ventilation (NIV) is the current standard therapy to manage respiratory insufficiency. Some MND patients however
do not tolerate NIV due to a number of issues including mask interface problems and claustrophobia. In those that
do tolerate NIV, eventually respiratory muscle weakness will progress to a point at which intermittent/overnight NIV
is ineffective. The NeuRx RA/4 Diaphragm Pacing System was originally developed for patients with respiratory
insufficiency and diaphragm paralysis secondary to stable high spinal cord injuries. The DiPALS study will assess the
effect of diaphragm pacing (DP) when used to treat patients with MND and respiratory insufficiency.
Method/Design: 108 patients will be recruited to the study at 5 sites in the UK. Patients will be randomised to
either receive NIV (current standard care) or receive DP in addition to NIV. Study participants will be required to
complete outcome measures at 5 follow up time points (2, 3, 6, 9 and 12 months) plus an additional surgery and 1
week post operative visit for those in the DP group. 12 patients (and their carers) from the DP group will also be
asked to complete 2 qualitative interviews.
Discussion: The primary objective of this trial will be to evaluate the effect of Diaphragm Pacing (DP) on survival
over the study duration in patients with MND with respiratory muscle weakness. The project is funded by the
National Institute for Health Research, Health Technology Assessment (HTA) Programme (project number 09/55/33)
and the Motor Neurone Disease Association and the Henry Smith Charity. Trial Registration: Current controlled trials
ISRCTN53817913. The views and opinions expressed therein are those of the authors and do not necessarily reflect
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Motor Neurone Disease (MND) is the third commonest
neurodegenerative disease with an annual incidence of
2-3 in 100,000 and prevalence of 5-8 per 100,000 [1-3].
Patients experience increasing muscle weakness affecting
the limbs, speech and swallowing, and breathing. As the
diaphragm and intercostal muscles become weak
patients experience sleep fragmentation and symptoms
of carbon dioxide retention. These consist of early
morning headaches, unrefreshing sleep and sleepiness
during the day [4,5]. These symptoms severely impact
on cognition and quality of life [6]. When respiratory
muscle weakness is advanced, patients can be breathless
at rest and are prone to recurrent chest infections. Se-
vere respiratory muscle weakness is a poor prognostic
sign and once the forced vital capacity (a measure of re-
spiratory muscle strength) reaches less than 50% of the
predicted value, mortality at 9 months ranges from 60%-
100% [7,8].
An important advance in the management of respira-
tory symptoms in MND has been the demonstration of
the beneficial effects of non invasive ventilation (NIV).
A randomised controlled trial demonstrated a median
survival benefit of approximately 7 months (p = 0.006),
in MND patients using NIV who had good bulbar func-
tion [9]. This survival benefit was accompanied by a sig-
nificant and sustained improvement in quality of life. As
experience with NIV has developed, areas of continuing
need have been identified which are not sufficiently
addressed by NIV alone:
a) MND patients with significant compromise of bulbar
function do not tolerate NIV and in the above trial of
NIV, no significant survival benefit was demonstrated
for this group [9].
b) Similarly some patients fail to tolerate NIV due to
claustrophobia and mask interface problems. In
addition although the NIV systems are ideal for
overnight use, during the day the mask interface can
interfere with communication and feeding and the
ventilator itself, although small, does restrict
mobility.
c) Eventually respiratory muscle weakness progresses to
a point at which intermittent/overnight NIV is
ineffective.
There is therefore, a need for additional complemen-
tary respiratory support to further aid respiratory muscle
weakness and so potentially provide a prolongation of
good quality life.
Diaphragm pacing (DP) is a technique initially devel-
oped for the treatment of respiratory muscle weakness
in patients with spinal cord injury [10]. In this patient
group it has allowed patients to reduce their time onmechanical ventilation or even remove the need for
mechanical ventilation [11]. The NeuRX RA/4 System is
a four channel percutaneous neuromuscular stimulation
system. Intramuscular electrodes are implanted laparo-
scopically into the abdominal surface of the diaphragm,
with leads tunnelled to an exit site on the abdomen. A
small external stimulator delivers the stimulus pulses
and provides respiratory timing. It is hypothesised that
the potential benefits of DP in MND may come from a
restoration of the coordination of respiration, lost as a
result of upper motor neurone dysfunction, as well as
conditioning of diaphragm muscle. In a healthy dia-
phragm slow twitch type I muscle fibres predominate.
Disuse and suppression of the diaphragm activity, due to
artificial ventilation, has been demonstrated to lead
quickly to atrophy and to a predominance of fast type
IIb muscle fibres [12]. The predominant type IIb mus-
cles fibres lead to inefficient uncoordinated diaphragm
contractions. In MND a similar process is likely to occur
due to disuse (secondary to UMN dysfunction) and sup-
pression of diaphragm activity due to NIV. DP may con-
dition the diaphragm with a conversion back to efficient
type I muscle fibres [13].
The anticipated benefits of DP in the MND patient
group are: improved survival; improved quality of life;
reduction in need for NIV; a less intrusive method of
providing respiratory support compared to NIV.
Diaphragm pacing
The NeuRx R/A4 device, has been utilized in over 350
patients to date, including two separate investigational
device exemption (IDE) trials [14]. There are over 275
patient years of cumulative use of the device with the
initial spinal cord injured (SCI) patient utilizing the de-
vice continuously for 10 years.
Efficacy evidence
A pilot feasibility study of 16 patients with MND
implanted with DP demonstrated provisional safety and
tolerability data and a decline in forced vital capacity of
0.9% per month following implantation, compared to
2.4% per month before the procedure [13]. One hundred
and six MND patients have been implanted with the
NeuRX RA/4 Device in a U.S. Food and Drug Adminis-
tration (FDA) prospective multi-centre trial. The
planned primary analysis of this study was the change in
rate of decline of FVC between lead-in (3 months) and
DP treatment (12 months) phases for patients not using
NIV. The full study results have not yet been published.
However subgroup data are available following approval
of DP for MND patients under the FDA Humanitarian
Device Exemption (HDE) Programme [14,15]. For this
approval, analysis was performed on a subgroup of
patients who met the Humanitarian Use Designation
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with a stimulatable diaphragm by voluntary contraction
or phrenic nerve conduction studies, and who were
symptomatic due to chronic hypoventilation (CH). The
physiological criteria for CH were FVC< 50%, or MIP
<60cm H20, or PaC02 ≥45mmHg, or nocturnal oximetry
demonstrating O2 saturations of ≤ 88% for 5 consecutive
minutes.
The median overall survival in the HUD subgroup
(n = 84) was 56 months from disease onset, 39 months
from diagnosis and 19 months from implantation of de-
vice. As part of the FDA HUD approval, survival of
implanted patients was compared with the standard care
NIV alone arm in a published study by Lechtzin et al
[16]. DPS HUD group patients with an FVC ≥ 45% but ≤
65% (n = 43) were selected for the comparison. The DPS
HUD group has an improved median survival of 16
months from diagnosis and 9 months from initiation of
NIV compared to the Lechtzin NIV group.
Safety and tolerability of DP
A total of 350 implantations in Spinal Cord Injured
patients and MND patients have taken place [14]. Gen-
erally implantation surgery is well tolerated. Detailed
safety data has been published on 51 patients with MND
who have undergone the implantation procedure (49 in
the FDA trial or pilot and 2 compassionate use cases). In
the trial/series the FVC at implantation ranged from
45%-89%, whereas the compassionate cases had an FVC
of 26% and 28%. All patients were extubated without dif-
ficulty and there was no 0 day or 30 day mortality [17].
Within the HDE approval submission safety analysis
was performed on the HUD subgroup (n = 86). There
were no reports of serious unanticipated adverse device
effects and no reports of any serious adverse effects
related to the patients’ use of the device following dis-
charge. There were 3 reports of serious adverse events
(3.5%) related to implantation. These were pneumo-
thorax (n = 2) requiring intervention and respiratory fail-
ure following surgical complications (n = 1) [14]. These
were previously recognised risks of laparoscopic
procedures.
Discomfort from pacing was reported in 22 patients
(26%). This was described as mild in 20 patients and se-
vere in 2 patients. Resolution was achieved in most cases
by adjusting the stimulation parameters.
Mild to moderate infection at the percutaneous exit
site was reported (n = 9, 9.3%). These were treated with
antibiotics. In two cases the subcutaneous wires needed
to be repositioned under local anaesthetic.
No serious adverse events occurred as a result of mal-
functioning device components. The following malfunc-
tions were reported; anode breaks (n = 18,21%), anode
falling out of body (n = 6,7%), external electrode breaks(n = 28, 33%), broken stimulators (n = 6, 7%) and broken
stimulator cables (n = 4, 5%) [14]. In practical terms in
MND, malfunctioning components resulted in a loss or
diminution of conditioning therapy until the malfunc-
tion was corrected. Design improvements have subse-
quently been implemented in an effort to improve
reliability and to simplify malfunction resolution.
The data presented with the HDE approval submission
are encouraging with regard to efficacy and safety of DP
in MND patients. However, an RCT is needed compar-
ing current standard care alone with DP in addition to
standard care. The aim of DiPALS will be to determine
whether DP in addition to NIV provides added benefit
for patients in terms of survival and quality of life out-
comes. We will conduct this trial in compliance with the
protocol, GCP and regulatory requirements.
Methods/design
Study design
DiPALS is a multi-centre prospective randomised con-
trolled interventional trial. The study has been approved
by the Cambridge Central Research Ethics Committee,
reference 11/EE/0226.
108 patients will be randomly allocated to receive ei-
ther standard care (NIV) or standard care with add-
itional DP in 5 centres. The participants will be male or
female above the age of 18 yrs. Use of the device in the
management of a patient’s respiratory dysfunction (de-
vice parameters, frequency and length of sessions) will
be managed at all centres. Participants will be requested
to attend visits in order to obtain safety, quality of life,
survival and health economic follow-up data at 2, 3, 6, 9
and 12 months post randomisation. This is a non com-
mercial, portfolio study supported by the DeNDRoN
(Dementia and Neurodegnerative Diseases Clinical Re-
search Network). It is funded by the HTA (Health Tech-
nology Assessment) Programme and the Motor Neurone
Disease Association and the Henry Smith Charity.
Primary research objective
The primary objective of this trial will be to evaluate the
effect of Diaphragm Pacing (DP) on survival over the
study duration in patients with MND/ amyotrophic lat-
eral sclerosis (ALS) with respiratory muscle weakness.
Secondary research objectives
The secondary objectives of this trial will be to evaluate
the effect of Diaphragm Pacing (DP) on:
 Quality adjusted life years (QALYs), as calculated by
combining EQ-5D and mortality data [18]. The
objective of the health economic analysis will be to
assess the cost-effectiveness of DP compared to
standard care in patients with ALS/MND. A cost-
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EQ-5D and mortality data from the trial. This will
be supplemented with decision analytic modelling to
estimate lifetime cost-effectiveness for the patient
cohort recruited to the trial.
 Quality of life of the patient, as assessed by the sleep
apnoea quality of life index (SAQLI), SF-36 [6,9] and
qualitative interviews.
 Quality of life of the main carer of the patient, as
assessed by the Caregiver Burden Inventory [19] and
qualitative interviews.
For each efficacy endpoint, the treatment effect will be
assessed by analysing the difference between groups over
the 12-month follow-up period, and the difference at 12
months.
The trial will also assess the safety and tolerability of
DP. Study endpoints safety (adverse events) and toler-
ability (patient withdrawal from treatment) will be
assessed at each time point over the course of the trial.
Please refer to Figure 1: Trial overview.
Subject population
Participants will be identified by the neurology or re-
spiratory clinicians at each site. Each potential partici-
pant will be given a study patient information leaflet
which will detail what will happen if they choose to take
part.
Inclusion criteria
Participants aged 18 or older may be recruited onto the
trial who have familial or sporadic MND/ALS diagnosed
as laboratory-supported probable, probable, or definite
according to the World Federation of Neurology El Es-
corial criteria. Female participants who are currently
pregnant or breastfeeding will be excluded. Participants
must be stabilised on Riluzole therapy for at least 30
days. Participants must have respiratory insufficiency as
determined by one or more of the following criteria:
a) Forced Vital Capacity (FVC) less than 75% predicted
b)Supine Vital Capacity (VC) less than 75% of sitting
or standing VC
c) Sniff Nasal Inspiratory Pressure (SNIP) less than 65
cmH2O men, or 55cmH2O women in the presence
of symptoms
d)Sniff Nasal Inspiratory Pressure (SNIP) less than 40
cmH2O
e) PaCO2 > 6kPa (daytime)
f ) Significant overnight O2 desaturation (>5% of night
with Sp02 <90% during overnight oximetery)
Additionally, an evaluation of bilateral phrenic nerve
function will be undertaken to ensure that the participanthas a stimulatable diaphragm. Clinical assessment indicat-
ing acceptable bilateral phrenic nerve function consists of
either absence of paradoxical abdominal wall movement
during a sniff maneuver and recording less than 10% de-
cline of FVC when moving from sitting to supine position,
OR on ultrasound evidence of at least 1 cm of downward
diaphragm movement independent of thoracic or abdom-
inal wall movement during the patient performing a sniff
manoeuvre (sharp inhalation through the nose).Exclusion criteria
Participants must not have a prior NIV prescription or a
pre-existing implanted electrical device such as pace-
maker or cardiac defibrillator. Any underlying cardiac,
pulmonary diseases or other disorders that would affect
pulmonary function tests independently of MND/ALS,
would increase the risk of general anaesthesia or ad-
versely affect survival over the course of the study will
be excluded. Significant decision making incapacity pre-
venting informed consent by the subject due to a major
mental disorder such as major depression, schizophrenia
or dementia are exclusions. Others include marked obes-
ity affecting surgical access to diaphragm or significant
scoliosis/ chest wall deformity and the involvement in
any respiratory trial that can influence the safety or out-
come measures of this study within three months of the
planned implantation of the device or during the year of
follow up. A pre-existing diaphragm abnormality such as
a hiatus hernia or paraoesophageal hernia of abdominal
contents ascending into the thoracic cavity is an exclu-
sion criterion. Patients with a forced Vital Capacity
(FVC) < 50% predicted or SNIP < 30 cmH2O who are
unable to perform FVC (bulbar patients) would be
excluded – because of potential anaesthetic risk. A pa-
tient is eligible for the study if all the inclusion and none
of the exclusion criteria are met.Recruitment, screening and consent
Potentially eligible MND patients with respiratory insuf-
ficiency will be identified by either the neurology or re-
spiratory investigator at the site. This will be either at a
clinic or from their clinic database. Patients who are
attending a routine clinic appointment will be ap-
proached about the study at this appointment with the
patient information sheet. Patients identified from the
clinic list, who are due to come in for a visit, will be sent
an information sheet in the post prior to their appoint-
ment. At the appointment the patient will be given an
opportunity to discuss the study in more detail and ask
any questions. All patients will be given as long as they
require to consider the Patient Information Sheet. After
this period, patients will be approached either by tele-
phone or in clinic, and the patient will be given the
Pat ient  ident ified fr om clinic by site study team member  and t r ial informat ion sheet  provided
Informed consent  sought  to undergo screening evaluat ion and par t icipat ion in t r ial
Pat ient  allocated (n=108) to t r ial arm via the web based
 randomisat ion system within 7 days of screening
Standard respirator y
care-NIV (n=54)
Standard respiratory care-NIV and Diaphragm Pacing
(n=54)
 1 week post  operat ive  follow up
Data collected at  2, 3,6,9 and 12 month follow up visits
 Safety and adverse event  data collected at  each t ime point
Data cleaning, analysis and repor t ing
Inser t ion of DP device and  surgical evaluat ion
Qualitat ive interview of 12 pat ients and 12 carers at  1 and 6
months post  implantat ion
Screening evaluat ion
Eligibility confirmed
Figure 1 Trial Overview.
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dures and the trial.
Consent will be obtained as either full written consent,
verbal consent given or consent given via the use of a
communication aid. Where non-written consent is
obtained an independent witness will be asked to sign
the consent form to verify the consent taken.
If the patient consents to the study a member of the site
study team (research nurse, respiratory or neurology con-
sultant) will initiate the screening process. The process
will involve assessing patient eligibility both against non-
clinical and clinical criteria and obtaining baseline assess-
ments. Patients who decline participation will be asked for
a reason for their non-participation to help determine
common reasons. This will help aid the recruitment strat-
egy as the trial progresses. We will collect basic details(age, gender, reason for exclusion) on all eligible patients
to allow completion of the CONSORT flow chart.
A member of the site study team will use the results of
the tests in order to assess patient eligibility against the
inclusion and exclusion criteria. Patients meeting all the
inclusion and none of the exclusion criteria will proceed
to randomisation. A member of the site study team will
randomise the participant within a week of screening.
The patient will be entered onto the study enrolment
log.
Web based randomisation system
The randomisation system is hosted on a secure virtual
server at The University of Sheffield and managed by epi-
Genesys (a wholly-owned subsidiary of the University).
Restricted access via the use of username and passwords
Figure 2 Participant flow within the trial.
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roles to allow only access to the relevant section of the
system to the owner of the account as appropriate. The
system records a full audit trail of all activities to discour-
age improper use and to identify the source of any such
use.
Method of randomisation
Participants will be randomised to either the treatment
arm (n = 54) or the control arm (n = 54). Patients will be
allocated their treatment by method of minimisation.
The minimisation factors will be baseline bulbar func-
tion, baseline FVC, age and sex. Patient details (ID, date
of birth and the factors above) will be entered into the
Sheffield Clinical Trials Research Unit (CTRU) web-
based randomisation system and the treatment alloca-
tion will be returned. Non-deterministic minimisation
will be employed by including a random element into
the allocation algorithm. The participant will be
informed of their treatment allocation within a week of
randomisation either by phone or letter. Please refer to
Figure 2 below for the screening and randomisation
process.
At randomisation arrangements will be made for both
NIV and DP insertion for trial participants. NIV initi-
ation will occur as per usual practice at the study site as
soon as possible following randomisation (within 1-2
weeks). For those randomised to the DP arm, a
provisional date for implantation will be allocated at ran-
domisation (within 2-3 weeks). Patients should be able
to use NIV prior to implantation. NIV should be avail-
able to patients in the anaesthetic recovery room post
implantation of the device.
Surgical implantation
In the DP arm participants will be admitted to hospital
for insertion of the DP device. A pre-operative safety
check will occur either during the admission or in the
week leading up to surgery. During the implantation
procedure, incisions of 0.5 to 1 inch long will be made
in the abdomen. More than one incision will be made so
instruments can be passed through the abdominal wall
as per standard laparoscopic procedure.
The surgeon will identify the best location to place the
electrodes within the diaphragm. A probe will be used to
temporarily place an electrode on the surface of the dia-
phragm and to stimulate the diaphragm muscle at sev-
eral locations. Once the best locations are identified, the
probe will be removed and two electrodes will be placed
in each side of the diaphragm muscle. The lead wires
from these electrodes will travel under the skin to the
abdominal wall. The wires will be trimmed so that the
ends sticking out of the skin are only 2 - 6 inches in
length. An x-ray will be taken following the surgery tocheck the position of the wires and to make sure no air
has travelled above the diaphragm and into the chest. At
the end of surgery the clinical station read out should be
printed out displaying a functioning stimulus connection
for each electrode wire. This will be used for surgical
quality control.
If the damage to the nerve supply to the diaphragm is too
great it is possible that the diaphragm will not be able to be
stimulated with the electrodes and diaphragm pacing sys-
tem. The assessments performed during screening are an
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ble. However, it is only possible to know for sure during the
operation. If during the operation it is clear that the dia-
phragm is not stimulatable then the operation will be
stopped and the device will not be inserted.
The training process is simple, as the technique is a
modification of a standard abdominal laparoscopic pro-
cedure. The clinicians who will be performing this pro-
cedure in the treatment arm are experienced surgeons
who will all be trained in the DP implantation technique
until they are competent to perform the procedure. This
training protocol has successfully worked in each of the
15 centres in the FDA study. It is currently standard
practice for a member of Synapse Biomedical to be
present at surgery when patients are fitted with DP. This
will be to provide technical support for the surgical pro-
cedure for trial participants.
Evaluation of electrodes and training
Evaluation of the electrodes and system will be per-
formed prior to discharge from hospital. A system check
of the wires will be completed. Electrode evaluation will
be performed by adjusting individual stimulus para-
meters (pulse amplitude, width, and frequency) using
the clinical station so that a comfortable level of stimula-
tion can be identified for the diaphragm conditioning
sessions. During the initial stimulation period, the parti-
cipant’s vital signs will be monitored for any abnormal-
ities. The patient will be given a daily target for the
number and length of diaphragm pacing sessions. This
will be recorded by the study team member in the pa-
tient diary.
Training of the participant and their caregiver will take
place prior to discharge. This will include instruction in
the care and use of the stimulator and data collection in
the patient diary. Verbal and written instruction will be
provided in a patient/caregiver instruction manual.
Prior to discharge, the participant /or carer must dem-
onstrate proficiency in: cleaning and care of skin, wires
and exit site; care and use of the stimulator; attachment
& detachment of all components and completion of the
Patient Diary.
The initial target for pacing sessions for MND patients
is 5 times per day with each session lasting at least 30
minutes. Patients should build up to this target over the
first month. In the second month patients should grad-
ually lengthen the training sessions. When using 6-7
hours a day patients should then switch from pacing
during the day to using the pacing device overnight
whilst asleep. At this stage patients can additionally use
the pacing device during the day if they feel benefit but
this is not essential. Patients should continue to use their
NIV as advised by their study doctor. A Patient Diary
will be given to the participant (upon NIV initiation) totake home to record the amount of time spent on DP
and/or NIV
Participant adherence
A member of the site study team will be responsible for
data collection at the various time points within the trial.
Predominantly the research nurses will be involved in
coordinating data collection activities and ensure com-
pliance with appointments. Following surgery a 1 week
follow up appointment will be booked for participants in
the treatment arm before they leave the hospital. At sub-
sequent follow up time points (2, 3, 6, 9 and 12 months)
where possible an appointment for the next time point
will be scheduled in. The research nurse will telephone
the participant 1 week before the appointment as a re-
minder where resource allows.
Withdrawal
Participants are free to withdraw from treatment or the
trial at any time. If a participant wishes to withdraw they
will be able to speak to a member of the site study team
i.e. respiratory or neurology consultants or the research
nurse. This will be documented on a participant with-
drawal form. Any data already collected during the
course of the trial up to the point of withdrawal will be
used in the final analysis. We will ask the participant for
their permission to continue to collect safety (i.e. adverse
event) data and data on survival.
Participants will have three options for study with-
drawal: withdraw from treatment but remain within the
study (all trial data would continue to be collected at
subsequent follow up time points as per protocol); with-
draw from study and unless the patient objects, any data
collected up to this point would be retained and used in
the study analysis and a final survival check will be per-
formed; withdraw from study entirely. Unless the patient
objects, any data collected up to this point would be
retained and used in the study analysis. If the patient
does not wish to be contacted with regard to safety or
survival, no further contact relating to the study will be
made.
Qualitative interviews
The qualitative component will draw directly upon both
patient and carer’s own experience and views, within the
context of everyday lives [20,21]. An essential part of
DiPALS is not only to demonstrate the efficacy of DP
but also to ensure that any extension of life is not to the
detriment of quality of life. The qualitative component
will complement the data collected by SF36 and SAQLI
for this purpose. The qualitative component will provide
information not easily obtained from questionnaires that
will facilitate the implementation of respiratory care
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study demonstrate benefit.
Design
A total of 12 patients and 12 carers will be recruited for
the qualitative component from those allocated to treat-
ment across all sites. Although eligibility of participants
for the main study will have been determined through
screening for the trial those selected for interview will
reflect the diversity of the MND population. This will in-
volve purposively selecting patients to reflect the vari-
ation within the predefined patient prognostic factors. It
is anticipated that MND patients will not be able to tol-
erate an interview in addition to follow up assessments
at local sites therefore an experienced research fellow
will conduct the interviews at a time and location that is
convenient for participants.
Ideally the patients and carers will be interviewed sep-
arately because they may have different views but joint
interviews will be undertaken if requested by the partici-
pants. The research team are experienced in working
with MND patients and appreciate the need for sensitiv-
ity whilst conducting the qualitative interviews with
these vulnerable participants.
Conduct
The in-depth interviews will be undertaken with DP
patients 1 and 6 months post implantation. The first
interview at 1 month will focus on the intervention and
the practicalities of having the implant fitted and adjust-
ing to life using the device. This information will be es-
sential to inform the clinical team of issues related to
both understanding the procedure including use of the
equipment and any beneficial or adverse impact it may
have.
A second interview will be undertaken at approxi-
mately 6 months post implantation. This will focus on
the impact the intervention has had on QoL. Changes to
QoL are reported to occur within this timeframe for all
MND patients. Six months is also considered an appro-
priate time to allow patients receiving DP (and care-
givers) to become familiar with the intervention and its
impact on QoL. Interviews will provide an opportunity
to take account of their views and experience of the
intervention.
Analysis
Data from the 48 qualitative interviews will be recorded,
transcribed and undergo Framework analysis [22]. Al-
though Framework analysis was developed for applied
policy it has proved useful in applied health research.
Analysis will be ongoing and iterative involving concur-
rent data collection and analysis, with systematic efforts
to check and refine developing categories of data.Themes identified in the early phases of data collection
will inform the areas of investigation in later interviews.
The emerging analysis will be discussed at regular team
meetings to identify recurring themes within the data
which will explore respondents’ underlying reasoning,
discuss deviant cases and reach agreement on recurrent
themes and findings.
Data collection
Once participants have been enrolled and allocated their
treatment the data collection process starts (Table 1).
Data collection occurs at baseline, 2, 3, 6, 9 and 12
months for both groups. Additionally the DP group will
undergo data collection at the time of surgery and 1
week following surgery. The subgroup of 12 participants
and carers who will be undertaking the qualitative sub
study will also undergo interviews at 1 and 6 months
post implantation.
Trial database - prospect
Prospect is a CTRU online Database system. Users are
able to perform data entry remotely via their secure ac-
count, access to which is restricted by use of an individ-
ual username and password. The study manager, data
managers, PI’s, co-investigators, research nurses and
administrators will have access to relevant anonymised
data. Data input will be the responsibility of the research
nurses. The system has a full electronic audit trail and
will be regularly backed up. The secure data manage-
ment system will incorporate quality control procedures
to validate the study data. Error reports will be generated
where data clarification is needed. Data quality will be
the responsibility of the Sheffield CTRU Trial Manager
and the Data Management Team.
Data handling and confidentiality
Detailed data management and data quality issues will
be set out in a data management and monitoring plan.
Data will be collected and retained in accordance with
the Data Protection Act 1998. Anonymised trial data will
be entered onto a validated database system designed to
an agreed specification between the Chief Investigator
and Sheffield CTRU. Output for analysis will be gener-
ated in a format and at intervals to be agreed between
Sheffield CTRU and the Chief Investigator. Trial docu-
ments will be retained in a secure location during and
after the trial has finished.
All source documents will be retained for a period of
at least 5 years following the end of the trial. Where trial
related information is documented in medical records
those records will be retained for at least 5 years after
the last patient last visit.
Monitoring and audit by the relevant health author-
ities will be permitted by the sponsor. These include the
Table 1 Data collection
Data collection tool Time point of study When
collected/
given to
patient
By who Purpose
Informed consent form Recruitment In clinic, face
to face
Neurology or
respiratory consultant
Ensure participants have been consented
appropriately
Screening and eligibility
assessment form
Recruitment/Screening In clinic Neurology or
respiratory consultant
or research nurse
Ensure protocol violations or deviations are avoided.
Include ECG, blood gases, blood test, FVC and
phrenic nerve evaluation tests
ALSFRSr Screening As above As above Allows minimisation on bulbar function
Survival 1 week, 2, 3, 6, 9, 12 months,
then finally at last follow up
for last patient
In clinic,
telephone
Research nurse Primary outcome measure
*EQ5D questionnaire
(patient and carer)
Screening, 2, 3, 6, 9 and 12
months
In clinic or
over the
phone
Neurology or
respiratory consultant
or research nurse
QALYs, secondary outcome measure
SF36 Screening, 2, 3, 6 and 12
months
As above As above Generic quality of life, secondary outcome measure
Sleep Apnoea Quality of Life
(SAQLI)
Screening, 2, 3, 6 and 12
months
As above As above Respiratory specific quality of life, secondary
outcome measure
*Caregiver Burden Inventory
questionnaire
Screening, 2, 3, 6 and 12
months
As above As above Secondary outcome measure
Side effects/ adverse event/
concomitant medications
and devices forms
All time points as required As above As above AE/SAEs
Healthcare resource use 2, 3, 6, 9 and 12 months As above As above Economic, secondary outcome measure
Patient Diary incorporating: 1 week, 2, 3, 6, 9 and 12
months
In clinic, at
hospital or at
home
Neurology or
respiratory consultant
and Patient and Carer
Main outcome Record DP and NIV use
* NIV use
* DP use and
* DP Parameters setting
NIV use Screening As above As above Main outcome
Medical history and
examination on CRF
Screening and 12 months In clinic Neurology or
respiratory consultant
Eligibility for trial, safety
Surgery evaluation form/ pre
op safety check
Screening, Surgery and 1
week
In clinic or
hospital
Neurology or
respiratory consultant
or Surgeon
Safety and eligibility for surgery
Surgical implantation/ intra
operative form
Surgery In hospital Neurology consultant
or Surgeon
Testing DP device in situ
Discharge evaluation form Surgery In hospital Neurology or
respiratory consultant
or surgeon
Demonstrate patient and carer competent to use
and care for DP device
DP parameters setting Surgery Clinic Neurology or
respiratory consultant
Evaluate the DP device, allow optimal use of device
*Qualitative interview
(n = 12, Patient and carer)
1 and 6 months post
implantation
Participants
place of
choice
Qualitative fellow Sub study outcome
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The sponsor will be allowed to monitor and audit the
trial at each site and be allowed access to source data
and documents for these purposes.
Adverse events
All adverse events will be reported in accordance with
the CTRU Adverse Event and Serious Adverse Events(SAE) SOP (PM004) which incorporate the Medicines
for Human Use (Clinical Trials) Regulations 2004 (SI
2004/1031) definitions. All trial participants will be
encouraged to contact and inform their site research
team if they experience any of the medical problems
outlined under SAE’s or relevant AE’s included (above).
Those that are not picked up through general contact
will be identified at follow up visits. A member of the
McDermott et al. BMC Neurology 2012, 12:74 Page 10 of 12
http://www.biomedcentral.com/1471-2377/12/74site study team will enquire about any adverse events
since the previous visit and record these on the adverse
event paper CRF and database. For any SAEs a paper
and database entry will be completed. The event will be
assessed by the local Principal Investigator and the form
will be kept in the site file. SAEs will be reported in the
periodic safety reports to the research ethics committee.
Standard or expected disease progression is an SAE ex-
clusion. Adverse events which must be reported include
chest infection requiring the use of antibiotics, infection
at the DP site or a revision of the DP device.
Statistics
Sample size
The sample size calculation is based on log-rank test,
using Simpson’s rule as implemented in Stata version
11.1 [23] to allow for the unequal length of follow-up
[24]. The study duration comprises an 18-month recruit-
ment period and a 12-month follow-up period, giving a
maximum follow-up of 30 months and a minimum of 12
months. Assuming control group survival proportions of
45%, 20% and 10% at the minimum, average and max-
imum follow-up times respectively, a hazard ratio of
0.45 and an additional 10% loss-to-follow-up, a total of
108 patients (54 per group) are needed to ensure a
power of 85% using a two-sided type I error of 5%. The
control group figures are conservative estimates based
on the sole randomised controlled trial of NIV, which is
now considered standard care in the UK. The FDA study
of DP in ALS/MND has estimated a one year survival of
86% after study entry for patients using DP and NIV
(personal communication). We have estimated the sam-
ple size on a conservative (but clinically important) 1-
year difference in survival of 45% versus 70%, which pro-
duces the estimated hazard ratio of 0.45. It is anticipated
that we will have complete survival data on all subjects
recruited, based on previous experience in MND trials.
With regard to quality of life data we anticipate a low
level of missing data due to loss to follow up. We have
reviewed the patients who were initiated on NIV in the
year up to Jun 2009 at the study sites and we have main-
tained contact with 100% of those patients surviving at
12 months. The appointment of a research nurse at each
study site will enable home visits if necessary to collect
the quality of life data. We have however allowed for a
10% loss to follow up in the sample size/power
calculation.
Data analysis
The primary outcome is overall survival, defined as the
duration from randomisation to death. This will be ana-
lysed by Cox regression, with covariates including treat-
ment group and the minimisation factors. As a
secondary analysis we will also report survival separatelyfor patients who are NIV tolerant and those who are
NIV intolerant. The proportionality assumption will be
assessed using time-dependent covariates and scaled
Schoenfeld residuals [25]. The change from baseline for
QoL outcomes will be analysed by two methods. The
first analysis will compare the change from baseline at
12-months using analysis of covariance (ANCOVA) in
which the treatment group and the baseline score are
included as covariates along with minimisation factors.
The second analysis will assess the QoL over the entire
12-month period by modelling the change from baseline
by repeated measures ANCOVA with the same covari-
ates. QoL will be summarised both with imputation for
missing data (in particular, assigning a score of zero fol-
lowing the date of death) and without. The safety and
tolerability profiles will be reported by analysing the pro-
portion of patients experiencing adverse outcomes. A
description of the statistical analysis of efficacy and
safety outcomes will be written in the trial Statistical
Analysis Plan by the trial statistician.Economic evaluation
A cost-utility analysis will be undertaken using the costs,
EQ-5D and mortality data from trial. The analysis will
take a NHS and Personal Social Services (PSS) perspec-
tive, with an additional analysis that incorporates carer
QALYs within the incremental cost-effectiveness ratio
(ICER). This will be supplemented with decision analytic
modelling to estimate lifetime cost-effectiveness for the
patient cohort recruited to the trial. Resource use for in-
sertion of the pacing system – theatre time, ward stay
and any critical care - will be gathered from theatre and
patient administration system (PAS) records. Resource
use relating to NIV and other NHS and PSS services will
be collected at all follow-up visits. Unit costs for inser-
tion will be based on hospital unit costs. Market prices
will be used for the pacing system and its associated
costs, with an equivalent annual cost being calculated
based on the lifespan of the system based on past experi-
ence. NIV costs will be based on business case and con-
tracting information relating to existing NIV services
within the participating centres. Other unit costs will be
taken from the most recent National Reference Costs,
British National Formulary and PSSRU publication ‘Unit
costs of health and social care’. The EQ-5D will be com-
pleted at baseline and all follow-up visits by patients and
the main carer of the patient. QALYs will be estimated
using straight line interpolation between data points.
Both costs and QALYs will be discounted at 3.5% per
annum. Mean incremental costs and QALYs will be
combined into an ICER, and sampling uncertainty repre-
sented by plots on the cost-effectiveness plane and asso-
ciated cost-effectiveness acceptability curves (CEACs).
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ation. An additional analysis will incorporate carer
QALYs within the ICER. A decision analytic model will
be constructed that will be validated by replicating the
results of the trial, and then results extrapolated to con-
duct a lifetime analysis. Extrapolation will use transition
probabilities estimated from a survival analysis based on
the 12 month follow-up data from the trial. Probabilistic
sensitivity analysis will be undertaken, with further de-
terministic analyses using SF-6D utilities and including
carer utilities. The feasibility of a mixed treatment com-
parison that includes DiPALS, the study by Bourke et al
(2006) and the ongoing Synapse study will be assessed.
This will form the basis of an additional cost-
effectiveness analysis if a valid comparison can be under-
taken. As with the trial based analysis, results will be
presented in terms of an ICER and CEACs.
Trial oversight
Three committees have been established to oversee the
conduct of the study: Trial Management Group (TMG),
Trial Steering Committee (TSC) and Data Monitoring
and Ethics Committee (DMEC). All committees are gov-
erned by Sheffield CTRU standard operating procedures.
The TMG consists of the Chief and Principal Investiga-
tors and key staff within the CTRU. The role of the
TMG is to implement all parts of the trial and to act on
the recommendations from the TSC and DMEC.
The TSC consists of the Chief Investigator, key staff
within the CTRU (as non voting members), an inde-
pendent chair and three independent members. The
roles of the TSC are to provide supervision of the proto-
col and statistical analysis plan, provide advice on and
monitor progress of the trial, to review information from
other sources and to consider recommendations from
the DMEC. The DMEC consists of an independent chair
and 2 independent members including a statistician. The
DMEC has responsibility for monitoring the results pro-
vided by the trial statistician to the plan described in the
trial protocol with reference to efficacy and safety,
reviewing information from other sources, providing
recommendations to the TSC on why the trial might be
modified or discontinued in terms of ethics and safety
and considering adverse events. There are no planned
interim analyses for the trial.
Monitoring arrangements
Trial set up and monitoring arrangements have been
agreed with the trial Sponsor (Sheffield Teaching Hospi-
tals). Monitoring assessments are planned at site initiation
and following the recruitment of a 3rd patient at each site.
Thereafter either an annual or a triggered visit will be per-
formed at sites to monitor their performance and perform
source data verification and data completeness checks. Allresearch governance approvals and contracts were
checked at site initiation prior to the initiation of
recruitment.
Ethical considerations
The trial received Research Ethics Committee favourable
opinion in July 2011. Trial sites (Sheffield Teaching Hos-
pitals, University Hospital South Manchester, Oxford
Radcliffe Hospitals, Newcastle Upon Tyne Hospitals and
Plymouth Hospitals NHS Trust) have locally approved
the study via local (Trust specific) site assessment. All
study documentation including approved patient infor-
mation sheets, consent forms, CRF’s and questionnaires
can be found in the local site file.
Indemnity and insurance
This trial will be conducted in accordance with the Med-
icines for Human Use (Clinical Trials) Regulations (SI
2004/1031). The trial has been financed by the HTA and
details have been drawn up in a separate agreement.
This is an NHS sponsored study. If there is negligent
harm during the clinical trial when the NHS body owes
a duty of care to the person harmed, NHS indemnity will
cover NHS staff, medical academic staff with honorary
contracts and those conducting the trial. The University
of Sheffield has in place insurance against liabilities for
which it may be legally liable and this cover includes any
such liabilities arising out of this clinical trial.
Reporting and dissemination
Results of the trial will be disseminated in peer reviewed
scientific journals and clinical and academic conferences.
Details of the trial will also be made available on the
study website. Summaries of the research will be
updated periodically to inform readers of the ongoing
progress.
Discussion and conclusion
This DiPALS study protocol will allow us to determine if
Diaphragm Pacing improves participant survival and
results in improved quality of life outcomes. Patient re-
cruitment began in December 2011 and the last patient
is expected to complete the trial in August 2014. The
study report will be written up by March 2015.
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